Your search returned 5 results.

Results
	1.	Association of Polymorphisms in FCGR2A and FCGR3A With Degree of Trastuzumab Benefit in the Adjuvant Treatment of ERBB2/HER2-Positive Breast Cancer: Analysis of the NSABP B-31 Trial. MedStar authors: Swain, Sandra M PMID: 27812689 Year: 2017 Citation: JAMA Oncology. 3(3):335-341, 2017 Mar 01 Institution: Washington Cancer Institute Medline publication type: Clinical Trial, Phase III Journal Article Multicenter Study Randomized Controlled Trial Form of publication: Journal Article All authors: Bandos H, Costantino JP, Fehrenbacher L, Finnigan M, Gavin PG, Geyer CE Jr, Jeong JH, Johnson NL, Kim SR, Lipchik C, Mamounas EP, Paik S, Pogue-Geile KL, Rastogi P, Song N, Swain SM, Wickerham DL, Wolmark N DOI: https://dx.doi.org/10.1001/jamaoncol.2016.4884 Add to cart (remove)
	2.	Aromatase inhibitor and tamoxifen use and the risk of venous thromboembolism in breast cancer survivors. MedStar authors: Barac, Ana PMID: 30659431 Year: 2019 Citation: Breast Cancer Research & Treatment. 174(3):785-794, 2019 Apr. Institution: MedStar Heart & Vascular Institute Medline publication type: Journal Article Form of publication: Journal Article All authors: Barac A, Chlebowski RT, Haque R, Shi J, Xu X DOI: https://dx.doi.org/10.1007/s10549-018-05086-8 Add to cart (remove)
	3.	Adjuvant therapy for high-grade, uterus-limited leiomyosarcoma: results of a phase 2 trial (SARC 005). MedStar authors: Priebat, Dennis A PMID: 23335221 Citation: Cancer. 119(8):1555-61, 2013 Apr 15. Institution: Washington Cancer Institute Medline publication type: Clinical Trial, Phase II Journal Article Multicenter Study Research Support, Non-U.S. Gov't Form of publication: Journal Article All authors: Araujo DM, Baker LH, George S, Hensley ML, Maki RG, Priebat DA, Soslow RA, Sutton G, Wathen JK DOI: http://dx.doi.org/10.1002/cncr.27942 Add to cart (remove)
	4.	Predicting degree of benefit from adjuvant trastuzumab in NSABP trial B-31. MedStar authors: Swain, Sandra M PMID: 24262440 Year: 2013 Citation: Journal of the National Cancer Institute. 105(23):1782-8, 2013 Dec 4. Institution: Washington Cancer Institute Medline publication type: Journal Article Randomized Controlled Trial Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Form of publication: Journal Article All authors: Bandos H, Blackmon NL, Bohn OL, Burandt E, Costantino JP, Fehrenbacher L, Fumagalli D, Gavin PG, Geyer CE Jr, Goldstein LC, Horne ZD, Jeong JH, Kim C, Kim SI, Kim SR, Lee A, Mamounas EP, Paik S, Pogue-Geile KL, Rastogi P, Reilly ML, Remillard MY, Romond EH, Sneige N, Swain SM, Tanaka N, Taniyama Y, Wickerham DL, Wolmark N DOI: http://dx.doi.org/10.1093/jnci/djt321 Add to cart (remove)
	5.	Lapatinib as a component of neoadjuvant therapy for HER2-positive operable breast cancer (NSABP protocol B-41): an open-label, randomised phase 3 trial. MedStar authors: Swain, Sandra M PMID: 24095300 Year: 2013 Citation: Lancet Oncology. 14(12):1183-92, 2013 Nov. Institution: Washington Cancer Institute Medline publication type: Clinical Trial, Phase III Comparative Study Journal Article Multicenter Study Randomized Controlled Trial Research Support, Non-U.S. Gov't Form of publication: Journal Article All authors: Atkins JN, Azar CA, Baez-Diaz L, Bandos H, Bear HD, Brufsky AM, Costantino JP, Farrar WB, Fehrenbacher L, Geyer CE Jr, Mamounas EP, Margolese RG, Paik S, Rastogi P, Robidoux A, Sarwar S, Shibata HR, Swain SM, Tang G, Wolmark N DOI: http://dx.doi.org/10.1016/S1470-2045(13)70411-X Add to cart (remove)

Powered by Koha